Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer

BACKGROUND: Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor monotherapy has been approved as second-line or later therapy in advanced non-small-cell lung cancer (NSCLC). The study aimed to compare the clinical outcomes of PD-1 inhibitor plus chemotherapy with PD-1/PD-L1 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Xiaoyang, Jing, Xuquan, Li, Ji, Tian, Yaru, Xu, Shuhui, Wang, Min, Zhu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554577/
https://www.ncbi.nlm.nih.gov/pubmed/33102221
http://dx.doi.org/10.3389/fonc.2020.556275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554577/
https://www.ncbi.nlm.nih.gov/pubmed/33102221
http://dx.doi.org/10.3389/fonc.2020.556275

Ejemplares similares